Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Unmet expectations: miR-34 plays no role in p53-mediated tumor suppression in vivo.

Jain AK, Barton MC.

PLoS Genet. 2012;8(7):e1002859. doi: 10.1371/journal.pgen.1002859. Epub 2012 Jul 26. No abstract available.

2.

Immortalized mouse embryo fibroblasts are resistant to miR-290-induced senescence regardless of p53 status.

Rizzo M, Evangelista M, Mariani L, Simili M, Rainaldi G, Pitto L.

Physiol Genomics. 2011 Oct 20;43(20):1153-9. doi: 10.1152/physiolgenomics.00064.2011. Epub 2011 Aug 16.

3.

Interaction of the oncogenic miR-21 microRNA and the p53 tumor suppressor pathway.

Ma X, Choudhury SN, Hua X, Dai Z, Li Y.

Carcinogenesis. 2013 Jun;34(6):1216-23. doi: 10.1093/carcin/bgt044. Epub 2013 Feb 5.

4.

miR-34: from bench to bedside.

Agostini M, Knight RA.

Oncotarget. 2014 Feb 28;5(4):872-81. Review.

5.

Mutant p53 exerts oncogenic effects through microRNAs and their target gene networks.

Li XL, Jones MF, Subramanian M, Lal A.

FEBS Lett. 2014 Aug 19;588(16):2610-5. doi: 10.1016/j.febslet.2014.03.054. Epub 2014 Apr 12. Review.

6.

Negative regulation of tumor suppressor p53 by microRNA miR-504.

Hu W, Chan CS, Wu R, Zhang C, Sun Y, Song JS, Tang LH, Levine AJ, Feng Z.

Mol Cell. 2010 Jun 11;38(5):689-99. doi: 10.1016/j.molcel.2010.05.027.

7.

miR-22 represses cancer progression by inducing cellular senescence.

Xu D, Takeshita F, Hino Y, Fukunaga S, Kudo Y, Tamaki A, Matsunaga J, Takahashi RU, Takata T, Shimamoto A, Ochiya T, Tahara H.

J Cell Biol. 2011 Apr 18;193(2):409-24. doi: 10.1083/jcb.201010100.

8.

P53/microRNA-34-induced metabolic regulation: new opportunities in anticancer therapy.

Zhang DG, Zheng JN, Pei DS.

Mol Cancer. 2014 May 21;13:115. doi: 10.1186/1476-4598-13-115. Review.

9.

p53 represses c-Myc through induction of the tumor suppressor miR-145.

Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, Elble R, Watabe K, Mo YY.

Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3207-12. doi: 10.1073/pnas.0808042106. Epub 2009 Feb 6.

10.

The p53/microRNA network in cancer: experimental and bioinformatics approaches.

Hünten S, Siemens H, Kaller M, Hermeking H.

Adv Exp Med Biol. 2013;774:77-101. doi: 10.1007/978-94-007-5590-1_5. Review.

PMID:
23377969
11.

Intact p53-dependent responses in miR-34-deficient mice.

Concepcion CP, Han YC, Mu P, Bonetti C, Yao E, D'Andrea A, Vidigal JA, Maughan WP, Ogrodowski P, Ventura A.

PLoS Genet. 2012;8(7):e1002797. doi: 10.1371/journal.pgen.1002797. Epub 2012 Jul 26.

12.

A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression.

Okada N, Lin CP, Ribeiro MC, Biton A, Lai G, He X, Bu P, Vogel H, Jablons DM, Keller AC, Wilkinson JE, He B, Speed TP, He L.

Genes Dev. 2014 Mar 1;28(5):438-50. doi: 10.1101/gad.233585.113. Epub 2014 Feb 14.

13.

p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest.

Braun CJ, Zhang X, Savelyeva I, Wolff S, Moll UM, Schepeler T, Ørntoft TF, Andersen CL, Dobbelstein M.

Cancer Res. 2008 Dec 15;68(24):10094-104. doi: 10.1158/0008-5472.CAN-08-1569.

14.

microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.

Zhang C, Liu J, Tan C, Yue X, Zhao Y, Peng J, Wang X, Laddha SV, Chan CS, Zheng S, Hu W, Feng Z.

Oncotarget. 2016 Feb 23;7(8):8783-96. doi: 10.18632/oncotarget.7088.

15.

Overexpression of microRNA-30b improves adenovirus-mediated p53 cancer gene therapy for laryngeal carcinoma.

Li L, Wang B.

Int J Mol Sci. 2014 Oct 29;15(11):19729-40. doi: 10.3390/ijms151119729.

16.

MiRNA-34 intrinsically links p53 tumor suppressor and Wnt signaling.

Cha YH, Kim NH, Park C, Lee I, Kim HS, Yook JI.

Cell Cycle. 2012 Apr 1;11(7):1273-81. doi: 10.4161/cc.19618. Epub 2012 Apr 1.

PMID:
22421157
17.

Breaking into the brachyury world: ΔNp63 joins in.

Sinha S.

Cell Cycle. 2010 Jul 1;9(13):2495-6. No abstract available.

PMID:
20647747
18.

miR-335 directly targets Rb1 (pRb/p105) in a proximal connection to p53-dependent stress response.

Scarola M, Schoeftner S, Schneider C, Benetti R.

Cancer Res. 2010 Sep 1;70(17):6925-33. doi: 10.1158/0008-5472.CAN-10-0141. Epub 2010 Aug 16.

19.

The big player governs small world too.

Lu X, Zhang X.

Cell Cycle. 2014;13(17):2655. doi: 10.4161/15384101.2014.948789. No abstract available.

20.

Metformin induces microRNA-34a to downregulate the Sirt1/Pgc-1α/Nrf2 pathway, leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agents.

Do MT, Kim HG, Choi JH, Jeong HG.

Free Radic Biol Med. 2014 Sep;74:21-34. doi: 10.1016/j.freeradbiomed.2014.06.010. Epub 2014 Jun 24.

PMID:
24970682

Supplemental Content

Support Center